Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

ABSTRACT: Until recently, no truly effective treatment options have existed for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), a serious disease with poor prognosis. In November 2013, the targeted multikinase inhibitor, sorafenib, was approved for use in these patients based on substantially improved progression-free survival compared with placebo. A number of other targeted agents, including lenvatinib, are being investigated in phase II and phase III trials. With the advent of these new treatment options, practitioners are faced with making important decisions in determining which patients are candidates for systemic treatment and the optimal timing for treatment initiation. Since patients may remain asymptomatic for a protracted period of time, tumor size a

SUBMITTER: Worden F 

PROVIDER: S-EPMC4206652 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature